Q-omics provides the consensus-scored MIR203A profile across patient tissues and cancer cell-line models. MIR203A expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR203A is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, MIR203A RNA expression shows 7,053 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, LUSC, and ESCA as cancer lineages where MIR203A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR203A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR203A survival associations across molecular data types. MIR203A RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR203A RNA expression–survival associations across cancer types. High MIR203A expression shows unfavorable associations in MESO, TGCT, COAD and GBM, but favorable associations in ESCA and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR203A RNA expression.
This table summarizes MIR203A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR203A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR203A shows lower tumor expression in THCA and LIHC and higher tumor expression in LUSC and COAD. The LUSC box plot shows higher MIR203A RNA expression in tumor versus normal tissue (log2 FC = +0.403, t-test p < 0.001).
This table shows molecular features associated with MIR203A in patient tissues and cancer cell lines. In patient samples, MIR203A shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
